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Abstract:  Although  Candida species  remain  the  relevant  cause  of  IFI,  other  fungi  (especially 
moulds) have become increasingly prevalent. In particular, 
of  mould  infections  but  also  Glomeromycota
increasing  in frequency, and  are associated with  high  mortality rates.  Many  of  these emerging 
infections  occur as  breakthrough  infections in  patients  treated with  new  antifungal  drugs. The 
causative pathogens, incidence rate and severity are dependent o
as on the geographic location of the patient population. France and Italy show the highest incident 
rates  of  Fusarium infections  in  Europe,  following  the  US,  where  numbers  are  still  increasing. 
Scedosporium prolificans, which primarily is found in soil in Spain and Australia, is most frequently 
isolated from blood cultures in a Spanish hospital. 
predominantly  found  in  Europe  with  especially  high  rates  in  Mediterranean  countr
increasing resistance to antifungal drugs especially of these new emerging pathogens is a severe 
problem for managing these IFIs.
Introduction: Invasive fungal infections (IFIs) are an 
increasingly important  clinical  dilemma,  engendering 
high rates of morbidity and mortality, particularly in 
immunocompromised  populations.  As  a  result  of 
growing  numbers  of  patients  with  a  variety  of  risk 
factors  (e.g.  transplantation,  chemotherapy,  HIV 
infection,  use  of  corticosteroids  or  new 
immunosuppressive agents), the incidence of IFIs has 
increased  substantially  in  recent  years.
example,  aggressive  new  therapies  for  transplant 
recipients and patients with hematologic malignancies 
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species  remain  the  relevant  cause  of  IFI,  other  fungi  (especially 
moulds) have become increasingly prevalent. In particular, Aspergillus species are the leading cause 
Glomeromycota (formerly  Zygomycetes)  and 
increasing  in frequency, and  are associated with  high  mortality rates.  Many  of  these emerging 
infections  occur as  breakthrough  infections in  patients  treated with  new  antifungal  drugs. The 
causative pathogens, incidence rate and severity are dependent on the underlying condition, as well 
as on the geographic location of the patient population. France and Italy show the highest incident 
infections  in  Europe,  following  the  US,  where  numbers  are  still  increasing. 
which primarily is found in soil in Spain and Australia, is most frequently 
isolated from blood cultures in a Spanish hospital. Geotrichum capitatum represents another species 
predominantly  found  in  Europe  with  especially  high  rates  in  Mediterranean  countr
increasing resistance to antifungal drugs especially of these new emerging pathogens is a severe 
infections (IFIs) are an 
increasingly important  clinical  dilemma,  engendering 
high rates of morbidity and mortality, particularly in 
immunocompromised  populations.  As  a  result  of 
growing  numbers  of  patients  with  a  variety  of  risk 
tion,  chemotherapy,  HIV 
infection,  use  of  corticosteroids  or  new 
immunosuppressive agents), the incidence of IFIs has 
increased  substantially  in  recent  years.
1,2,3,4,5,6,7 For 
example,  aggressive  new  therapies  for  transplant 
matologic malignancies 
have  led  to  more  profound  immunosuppression  of 
longer duration.
7
In addition, advances in medical care are extending 
the  survival  of  critically  ill  patients,  rendering  them 
more  vulnerable  to  IFIs.
severity of IFIs as well as the causative pathogens are 
dependent  on  various  risk  factors  concerning  the 
patient such as the underlying condition, the state of 
immunosuppression, but also the geographic location 
of the patient.
2,6,10
A wide variety of pathogens can
IFIs. Historically, Candida species have by far been the 
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of IFIs as well as the causative pathogens are 
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most  common  infective  organisms  among  fungi. 
However, the epidemiology has changed dramatically 
in recent years: IFIs caused by moulds – predominantly 
Aspergillus species - have increased substantially and 
newly  emerging  and  rare  fungal  pathogens  such  as 
Glomeromycota (e.g.  Rhizopus and  Mucor species), 
hyaline  moulds  (e.g.  Fusarium species)  and  other 
opportunistic species (e.g. Scedosporium species) are 
increasingly  being  reported.
7,8,11,12 This  article  will 
predominantly review the most common causatives of 
IFIs, concentrating on  the  changing epidemiology  of 
fungal infections and focusing on surveys carried out in 
the Mediterranean area. 
Yeasts and Yeast-Like Pathogens
Candida  species: Candida  infections  are  the  most 
frequent cause of IFIs worldwide, with a case rate of 
72.8 per 1,000,000 per year
13 and can result in a wide 
range  of  clinical  symptoms,  from  mucocutaneous 
overgrowth to blood stream infections and metastatic 
infections.
8,14,15 More than 100 Candida species have 
been  found  to  be  pathogenic  with  their  frequency 
varying according to the geographic setting.
16,17,18,19
The  burden  of  invasive  candidiasis  remains 
substantial; after a decline in mortality throughout the 
early to mid 1990s, mortality rates have leveled off in 
recent years.
13 In the United States, Candida species 
are the fourth most common cause of nosocomial blood 
stream infection.
13 Candida (C.) albicans remains by 
far  the  most  common  species  causing  invasive 
candidiasis  worldwide  (62%  in  2003)  although  the 
frequency  of  candidiasis  caused  by  other  species 
including  C.  tropicalis,  C.  parapsilosis,  C.  glabrata, 
and C. krusei has been increasing steadily over the last 
10  years.
13 Two studies in  Italy and  Spain  show the 
distribution of  Candida species in the Mediterranean 
area  which  was  shown  to  be  generally  similar  to 
reports from other European countries.
20,21,22,23
An Italian study
21 revealed, that C. albicans (61 % 
of  all  isolates)  was  followed  by  C.  parapsilosis,  C. 
glabrata and C.tropicalis, which is similar to reports 
from  other  European  countries,  with  the  only 
difference that here C. glabrata was shown to be the 3
rd
most common species, while it is the 2
nd most common 
in Switzerland,
24 the UK
25 and the US.
26 Interestingly, 
in  a  Spanish  study,  carried  out  in  Barcelona,  C. 
glabrata was shown to be only the 4
th most common 
species,  with  C.  tropicalis being  the  3
rd and  C. 
parapsilosis the  2
nd most  common  following  C. 
albicans.
27 The same Spanish study
27 revealed, that the 
overall incidence of bloodstream infections caused by 
Candida in Barcelona is lower (4.3 cases per 100 000 
population)  than  in  the  US  (6-10  per  100  000 
population).
3,28,29 Nevertheless,  the  number  of 
incidence in  Spain correlated well with reports from 
Northern European countries.
30,31 Candida bloodstream 
infections are in general very high among neonates and 
infants.
20,27,32 With 38.8 cases per 100 000 population 
the number of incidence in Barcelona/Spain is within 
the  range  of  numbers  obtained  from  studies  in  the 
US.
26 However, C. parapsilosis was the most common 
species  isolated  from  neonates  in  Spain  (67%  of  all 
cases)
20, whereas in the US C. albicans was the most 
common species and the proportion of C. parapsilosis
infections  was  significantly lower  (27-45%)  than  in 
Spain.
20,28,29
Since the 1990s, fluconazole has been widely used 
for  both  treatment  and  prophylaxis  of 
immunosuppressed  patients  resulting  in  decreasing 
rates  of  Candida bloodstream  infections  worldwide. 
The downside of this application was that C. glabrata, 
being  less  susceptible  to  fluconazole,
3,33 as  well  as 
other non-albicans infections are emerging, such as C. 
krusei which is fluconazole resistant.
34 In a nationwide 
surveillance study in Spain the frequency of antifungal 
resistance was determined next to species distribution 
and incident rates. This study revealed that 7 % of all 
isolates  exhibited  decreased  susceptibility  to 
fluconazole  with  a  linear correlation  to  voriconazole 
resistance. Furthermore, MICs for voriconazole where 
increased in patients that received fluconazole before, 
than  in  those  without  previous  exposure  to 
fluconazole.
35 Another Spanish study investigated the 
susceptibility  to  voriconazole  of  more  than  4000 
clinical  Candida isolates  according  to  EUCAST 
testing,  and  revealed  that  among  C.  albicans,  C. 
parapsilosis and  C.  tropicalis resistance  to 
voriconazole  was  uncommon  (with  a  maximum  of 
11%), but higher MICs were obtained for C. glabrata
and C. krusei.
36 The antifungal susceptibility of the C. 
parapsilosis,  which recently  was  found to  consist  of 
three  different species, namely  C.  parapsilosis sensu 
strict, C. metapsilosis and C. parapsilosis, was shown 
to  be low for echinocandins.
37,38 A Portuguese study 
testing 175 clinical and environmental isolates of the 
C. parapsilosis group showed that the majority (91.4 
%) of all isolates are C. parapsilosis sensu stricto, and 
of those most isolates were susceptible to fluconazole. 
All of the isolates C. metapsilosis and C. parapsilosis
were susceptible to azoles and amphotericinB, while a 
high number was non-susceptible  to echinocandins.
38
The  10  year  ARTEMIS  DISK  global  antifungal 
surveillance study, where 256 882 isolates of Candida 
sp. were collected from 142 sites in 42 countries and 
tested against fluconazole, showed that the frequency 
of azole resistance varied considerably by geographic 
region.
39 Higher rates of resistance to both fluconazole 
and  voriconazole were  found  in  isolates  from  North 
America.  Not  only  for  C.  glabrata and  C.  krusei
decreased  susceptibility  was  shown,  but  also  for  C. Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
guilliermondii, C. inconspicua, C. rugosa and others, 
demonstrating  that  13  out  of  the  31  species  found 
exhibited  increased  resistance  to  fluconazole.  As 
described before, cross- resistance between fluconazole 
and  voriconazole  is  evident  and  seems  to  be  more 
pronounced  in  some  species  of  Candida than  in 
others.
39
Cryptococcus  species:  The  genus  Cryptococcus
includes  encapsulated  yeasts  that  lack  a 
mycelium.
40,41,42 Infection  is  usually  initiated  in  the 
pulmonary  tract  with  later  possible  dissemination, 
usually  to  the  CNS,  causing  meningitis.
43,44
Involvement  of  parenchyma  of  the  brain  and 
meningitis occurs in between 40 and 86% of patients.
44
Cryptococcosis  usually  occurs  in  patients  with 
impaired immunity.
44 The concern about Cryptococcus
sp. has dramatically increased as it still remains one of 
the most common life threatening fungal infections in 
HIV- patients,  where  the  risk  of  a  Cryptococcus
infection is between 2.9 – 13.3%. In non-HIV infected 
individuals,  incidence  rates  of  0.2–0.9%  have  been 
reported  in  the  United  States.
44 Patients  with  AIDS 
have a much higher risk of infection (2.9–13.3%). In 
non  – AIDS  patients,  but  those  with  hematologic 
malignancies,  administration  of  steroids  and  diabetes 
mellitus were the most frequent risk factors (6 and 4 
out of 17 patients, respectively), as demonstrated in a 
retrospective  study  conducted  in  Italy  between  1993 
and 2002.
45
In SOT recipients, an incidence of 2.8% has been 
reported.
44 Risk factors for mortality are pre-existing 
renal failure and liver failure in transplant recipients.
44
In humans two Cryptococcus species can provoke 
disease: C. neoformans and C. gattii, which include 5 
different  serotypes  altogether.  Two  varieties  of  C. 
neoformans (C.  neoformans  var.  neoformans and  C. 
neoformans  var.  grubii)  representing serotypes  D,  A 
and AD (a hybrid from of both A and D), respectively, 
have been isolated.
42,46,47 C. gattii was previously listed 
as  a  further  variety  of  C.  neoformans,  but  is  now 
known  to  be  a  distinct  species.  C.  gattii includes 
serotypes  B  and  C,  both  commonly  seen  as  true 
pathogens provoking disease also in immunocompetent 
persons.
41,46,48
C. neoformans has a worldwide distribution and has 
been isolated from a variety of environmental sources, 
mainly  from  bird  excreta,  where  the  microorganism 
can survive for a long time due to protection from sun 
and  high  temperatures.  Its  capsule  even  makes  it 
resistant  to  natural  drying  of  the  vector  matter.  The 
distribution of C. gattii was thought to be  restricted to 
tropical and subtropical environments, often associated 
with  Eucalyptus trees  and  the  koala  bear.
49 Yet,  in 
recent  years,  an  outbreak  of  C.  gattii  infections  has 
been  reported  from Vancouver  Island/Canada,  where 
more than 66 human cases with at least 4 fatalities have 
been reported in otherwise healthy persons, all due to 
infections  with  serotype  B.
50 In  recent  years,  some 
other species such as C. laurentii and C. albidus were 
isolated from cryptococcosis patients.
51,52
High mortality rates of 30-40%
41 are mainly due to 
the  difficulty  in  killing  the  pathogen.  Without 
treatment, the invasive infection is fatal, which makes 
rapid  diagnosis  and  treatment  inevitable.  A 
combination  of  amphothericin  B  and  flucytosin, 
followed  by  fluconazole  maintenance  therapy  is  the 
therapeutic option in most cases,
53 although C. gattii
was found to show resistance to amphotericin B and 
fluconazole.
54 Furthermore,  a  trend  of  increasing 
fluconazole resistance of C. neoformans isolates from 
the  Asia-Pacific,  Africa/Middle  East, and  Latin 
America regions but not among isolates from Europe 
or Northern America has been described in a 10 year 
antifungal surveillance study.
55
Trichosporon species: Systemic trichosporonosis is a 
relatively uncommon but frequently fatal opportunistic 
fungal infection in immunocompromised individuals.
56
The taxonomy of the yeasts that cause trichosporonosis 
has  been  extensively  revised.
56,57 It  is  now  widely 
accepted that the previously named Trichosporon (T). 
beigelii actually consists of six species: T. asahii, T. 
asteroides, T. cutaneum, T. inkin, T. mucoides, and T. 
ovoides. Geotrichum capitatum, originally considered a 
species of Trichosporon and now reclassified, is also a 
common  cause  of  trichosporonosis.
56 While  any 
immunocompromised  patient  can  develop  invasive 
trichosporonosis,  the  risk  is  highest  for  those  with 
hematologic  malignancies.
58,59 Incidence  rates  of  0.4 
and  0.5%,  respectively,  for  infections  due  to 
Trichosporon sp. and G. capitatum have been reported 
in  patients  with  leukemia.
59 One  of  the  largest 
multicenter  retrospective  studies  on  invasive 
trichosporonosis,  carried  out  in  Italy,
56 revealed  that 
acute  myeloid  leukemia  was  the  most  frequent 
underlying hematologic disease for trichosporonosis. A 
total  of  17  of  the  52  patients  with  hematological 
malignancies were diagnosed with infections caused by 
Trichosporon sp., while the majority of infections (35 
out of 52) was attributed to G. capitatum. Furthermore, 
the study showed that the frequency of Trichosporon 
sp.  infections  is  similar  on  all  continents,  while  G. 
capitatum is predominantly a European pathogen, with 
high  rates  especially  countries  of  the  Mediterranean 
area.
56 Several  Trichosporon  sp.  were  shown  to  be 
multidrug resistant.
56 Echinocandins have poor activity 
against  Trichosporon sp.  as  demonstrated  by  high 
MICs
58 and  breakthrough  cases  in Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
immunocompromised  patients  treated  with 
caspofungin
59,60,61 or micafungin
61 have been reported.
Moulds 
Aspergillus species:  Aspergillus  species  are 
opportunistic moulds that can cause both allergic and 
invasive  syndromes.
62 More  than  300  Aspergillus
species are known today of which only a small number 
cause  opportunistic  infections.
62 The  most  common 
species  causing  aspergillosis  is  Aspergillus  (A.) 
fumigatus,  accounting  for  approximately  90%  of 
Aspergillus infections.
63 Depending  on  regional 
distinctions A. flavus, A. nidulans and A. terreus are 
frequently reported as well, and there is evidence that 
these  non-fumigatus  pathogens  are  increasingly 
common etiologic  agents.
63,64,65 There  are differences 
in the clinical presentations produced by these different 
species.
For example, A. flavus produces a disproportionate 
number of infections in the paranasal sinus, while A. 
nidulans is a common culprit in chronic granulomatous 
disease.
63 Although  A.  terreus remains  uncommon, 
infection  caused  by  this  pathogen  is  associated  with 
high  mortality  rates  because  of  its  resistance  to 
amphotericin  B.
64 A  study  including  three  European 
countries,  namely  Austria,  Denmark  and  Spain, 
revealed that A. terreus seems to be endemic for Tirol, 
Austria as it was exclusively found in hospital samples 
from Austria.
66 In Spain/Madrid A. niger was the most 
isolated  non-fumigatus  species.  Furthermore,  it  was 
shown  that  azole  resistance  of  Aspergilli is 
significantly  increasing,  especially  in  the  UK 
(Manchester)  and  the  Netherlands  (Nijmegen).  The 
Dutch  study,  involving  almost  2000  A.  fumigatus
isolates  collected  over  a 14-year  period  in  the 
Netherlands, of which 32 isolates exhibited increased 
resistance to all azoles tested, showed that 30 of the 32 
strains had the same “dominant resistance mechanism”. 
They all exhibited a single amino acid change in the 
cyp51A gene (encoding the target enzyme cytochrome 
P450 sterol 14-α-demethylase) and an alteration in the 
promoter region of this gene. Six isolates out of 317 
from other European countries also exhibited resistance 
to  itraconazole.  In  a  study  by  Pfaller  et  al.  1789 
Aspergillus isolates  from  centers  all  over  the  world 
between  2001  and  2009  were  evaluated  for  their 
susceptibility to triazoles (voriconazole, posaconazole, 
itraconazole).  For  each  of  the  three  triazoles  tested, 
decreased  susceptibility  was  observed  and  varied 
according to  the  species. 49  isolates exhibited MICs 
higher than 4 µg/ml for itraconazole, of which some 
were shown to be cross resistant to posaconazole and 
voriconazole.
68 There exist clinical reports on primary 
invasive Aspergillus infections due to resistant isolates 
involving various manifestations, e.g. in the lung, the 
brain, in bones.
69,70,71,72,73 Furthermore, cases have been 
shown, where itraconazole treatment is lacking clinical 
efficacy in  patients  with  aspergilloma.
71,74 In Austria 
the  occurrence of  azole  resistance among  clinical  A. 
fumigatus is 0% while in Spain it is 2%. Reasons for 
this  increase  in  resistance  are  not  clear  yet, 
nevertheless there exists some evidence that it is due to 
excessive use of azoles in agriculture.
75,76
Invasive aspergillosis has remained the predominate 
cause of invasive mould infections over the last 10–15 
years.
77 Reasons for this include a continued increase 
in high-risk populations such as solid organ transplant 
(SOT) and hematopoietic stem cell transplant (HSCT) 
recipients,  HIV-infected  individuals,  and  those 
receiving  intensified  chemotherapy  regimens.
2,63,78,79
Invasive aspergillosis is associated with a high rate of 
mortality,  however,  there  is  some  evidence  that 
survival  rates  have  increased  in  recent  years  among 
those undergoing HSCT, primarily because of the use 
of non-myeloablative conditioning regimens, the use of 
peripheral blood stem cells, prompt diagnosis, and the 
use of effective antifungal therapy.
6
An Italian study on invasive aspergillosis in AML-
patients (SEIFEM-2008 registry study)
80 showed that 
there is  a clear downward  trend in  the aspergillosis-
attributable  mortality  rate.  In  various  consecutive 
multicenter  studies  Pagano  et  al.  showed  a  decrease 
from  48%  (1987-1998),  to  38.5%  (1999-2003)  and 
27% (2004-2007).
5,80,81,82 It is important to note, that 
according to the latest study,
80 about two-thirds of the 
patients  developed  invasive  aspergillosis  despite 
standard antifungal prophylaxis based on fluconazole 
and  itraconazole,  which  points  out  that  the  use  of 
systemic  prophylaxis  needs  to  be  further  discussed. 
Independently from whatever prophylaxis was applied, 
A.fumigatus was  the  most  causative  species  of 
aspergillosis in the Italian study.
Fusarium species: Fusarium sp. can be found in soil, 
plants and air. Clinical manifestations are diverse and 
depend  largely  on  the  immune  status  of  the  patient. 
Often, Fusarium sp. affects the skin (70-90%), lungs 
and sinuses (70-80%). Fusariosis is a life-threatening 
and  increasingly  important  mycosis  in 
immunocompromised hosts.
82,83,84 Risk factors for such 
infections  are  skin  lesions,  burns,  use  of 
corticosteroids,  prolonged  neutropenia  and 
hematological  malignancy.
12,84,85,86 Fusarium sp.  are 
angiotropic  and  angioinvasive  moulds  that  produce 
hemorrhagic  infarction  and  low  tissue  perfusion, 
resulting in tissue necrosis.
83 More than 50 species of 
Fusarium have  been  identified  but  only  a  few  are 
pathogenic  in  humans.
83 These  include  F.  solani
(causes 50% of cases), F. oxysporum, F. moniliforme, 
F. verticillioides, F. dimerum, and F. proliferatum.
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In  terms  of  global  occurrence,  fusariosis  is  most 
common in the United States (50–80% of all cases), 
followed  by  France,  Italy,  and  Brazil.
83,87,88 In  the 
SEIFEM-2004  survey,  Fusarium species  were 
responsible  for  0.1%  of  infections,  the  majority  in 
AML  patients  (0.3%).
81 In  another  Italian  study, 
including  14  haematological  centers,  Fusarium
infection  was  documented  in  6  out  of  351  patients 
(1.7%),
88 with  aplastic  anaemia  and  AML  as  the 
underlying diseases (3 cases each). While the incidence 
in  Italy  remains  stable,  it  increased  in  some  US 
centers.
84 Because the clinical presentation of fusariosis 
may  be  non-specific,  differentiating  it  from  invasive 
aspergillosis can be challenging.
83 More than 90% of 
cases of fusariosis have been reported in neutropenic 
patients  with  hematologic  malignancies.
88 Incidence 
rates  of  0.06%  (acute  leukemia),  0.2%  (autologous 
bone marrow transplant [BMT]), and 1.2% (allogeneic 
BMT)  have  been  reported.
82 In  patients  with 
hematologic  malignancies,  persistent  neutropenia 
(hazard ratio [HR] = 5.43) and use of corticosteroids 
(HR  =  2.18)  were  the  most  important  predictors  of 
mortality. Ideal treatment of fusariosis is still unclear. 
Azoles  and  polyenes  seem  to  be  most  effective. 
Nevertheless, Fusarium sp. exhibit high resistance to 
antifungal drugs.
81,84,89
Scedosporium  species:  Scedosporium sp.  are 
ubiquitously  distributed  worldwide,  commonly  found 
in soil, sewage or polluted water. S. apiospermum (also 
known  by  its  teleomorphic  name  Pseudoallescheria 
boydii) and S. prolificans have the greatest impact in 
human infections.
12,90 These two species differ in their 
epidemiological  niches,  morphology  and  antifungal 
sensitivity  and  can  cause  infections  in  both 
immunocompetent  and  immunosuppressed 
populations.
85,90 S.  apiospermum has  a  worldwide 
distribution  usually in  association with  water, and is 
therefore often reported as a cause of pneumonia and 
disseminated infection in near-drowning victims.
91 On 
the other hand, S. prolificans is found in soil, mainly in 
Spain and Australia.
92 In a Spanish survey, conducted 
between 1990 and 1999, S. prolificans was the most 
frequent  filamentous  fungi  isolated  from  blood 
cultures,
93 comprising 5.2% of all of the filamentous 
fungi  isolated  in  the  respective  hospital  (San 
Sebastion/Spain).
93
Mycetoma,  a  disfiguring,  but  non-life-threatening 
infection of the skin and subcutaneous tissue, is one 
type of disease caused by S. apiospermum, frequently 
developed through thorn punctures, wood splinters or 
preexisting  trauma.
11,12,85 Pseudallescheriasis  or 
scedosporiosis  is  mainly  found  in 
immunocompromised  patients  with  hematological 
malignancies or in organ transplant recipients. For 11 
%  of  cases  in  SOT  recipients  fungemia  with 
Scedosporium  sp.  was  reported.
11 Interestingly, 
neutropenia  was  not  a  variable  in  connection  with 
Scedosporium infection  in  SOT  patients.  Also  S. 
prolificans was  found  to  cause  deep  invasive 
disseminated infections associated with high mortality 
rates.  Dissemination  throughout  the  body  might  be 
easier for this organism due to its ability to produce 
conidia  in  tissue.
12 Both  pathogenic  species  of 
Scedosporium  are  highly resistant  to  amphotericin  B 
and  echinocandins,  with  S.  prolificans  being  highly 
resistant  to  almost  all  of  the  currently  available 
antifungal  drugs.  Voriconazole  seems  to  have  the 
strongest  effect  on  both,  S.  apiospermum and  S. 
prolificans,  although  most  data  exist  from  in  vitro 
studies, where MICs for S. prolificans are at a level 
that would not be achieved in human compartiments 
and not be beneficial for the patient. As an approach, 
synergistic killing was investigated with a combination 
of  voriconazole  and  terbinafine,  which  might  be 
worthwhile to try.
12,85,94,95,96,97  Hence, mortality rates 
have been reported to  be as high as 65-75 % for S. 
apiospermum and  even higher  (85-100%)  for  S. 
prolificans.
Glomeromycota  (formerly  Zygomycetes):  Infections 
with species of the Glomeromycota (medically referred 
to  as  zygomycosis  or  mucormycosis)  play  an 
increasingly  important  role  in  immunocompromised 
patients.  Two  orders  of  the  Glomeromycota  are 
clinically  relevant:  Mucorales and 
Entomophthorales.
98,99,100 Members  of  the  Mucorales
are distributed worldwide while Entomophthorales are 
generally  limited  to  the  tropics  and  subtropics.
101,102
Species provoking human disease mostly belong to the 
group  of  Mucorales,  which  is  characterized  by  a 
rapidly  evolving  course,  tissue  destruction,  and 
invasion  of  blood  vessels.
101,103 The  most  common 
species  causing  mucormycosis  are  Rhizopus  (R.) 
arrhizus (R.  oryzae),  R.  microsporus  var. 
rhizopodiformis,  and  R.  pusillus.  Other  causative 
species  include  Absidia  corymbifera,  Mucor  species, 
and Cunninghamella bertholletiae.
101 Mycoses caused 
by  Entomophthorales are  more  indolent  and 
chronically progressive.
101,103
Commonly  infections  affect  the  paranasal  sinus 
(39%), the lungs (24%), and the skin (19%) with the 
primary  site  of  infection  depending  on  the  patient 
population.
7,104 Disseminated  disease  is  reported  in 
approximately  one-fourth  of  patients,
104 resulting  in 
high  mortality  rates  (96%).
7 A  case-control 
observational study found that prolonged neutropenie 
rather than a low neutrophil count is more common in 
patients with zygomycosis.
104 Frequent underlying risk
factors are diabetes mellitus, particularly enhanced byMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1. Risk factors and mortality rates of IFIs caused by new emerging pathogens.
pathogen
comments
Mortality rate (%) patient population important facts
Cryptococcus gattii
Trichosporon species
Fusarium species
Scedosporium species
Glomeromycota
non-immunosuppressed patients
hematological malignancies,
neutropenia, SOT
skin leasons and burns, 
neutropenia, hematological 
malignancies, contact lenses, 
HSCT, SOT, corticosteroid 
treatment
near drowning victims 
(pneumonia and disseminated 
infection)
hematological malignancies, SOT
hematological malignancies
diabetes mellitus, neutropenia, 
SOT, HSCT
immunocompetent patients
pulmonary infections
outbreaks all due to serotype B
expansion of natural habitat
resistance to amphotericinB and 
fluconazole
opportunistic infection (part of human skin 
flora)
multi drug resistance
high MICs for echinocandins
breakthrough infections in 
caspofungin/micafungin treated 
populations
multidrug resistance
positive blood culture
associated with water (S. apiospermum)
multidrug resistance
infection of skin and subcutaneous tissue 
(mycetoma)
positive blood culture
iron chelator deferoxamine as possible  risk 
factors
multifactorial treatment strategy necessary
6
50
65 
56
70 – 78 
89
65 – 100 
90
47 
99
ketoacidosis,  hematological  malignances  and  bone 
marrow  or  solid  organs  transplantation.
85,101,104
Diabetes  still  remains  the  most  common  risk  factor 
with 36% to 88% among mucormycosis-cases having 
diabetes as a predisposing condition.
101 However, the 
cases of mucormycosis in patients with hematological 
malignancies or those who have received hematopoetic 
stem cell or SOTs is dramatically increasing in the past 
two  decades.
85 Invasive  mucormycosis  is  now 
considered to be the 2
nd most frequent mould infection 
in  patients  with  hematological  malignances,  with 
reported cumulative incidence ranging from 0.1 – 2.5 
% in different series.
104 An Italian study reports that 45 
(11.5%)  out  of  391  patients  with  hematological 
malignancies  had  infections  with  a  representative  of 
the Mucorales.
105 In France the incidence rate within 
this  patient  group  increased  of  24  %  per  year  from 
1997 to 2006.
106 The so far largest and geographically 
most diverse study on epidemiology of zygomycosis in 
Europe, including 15 countries and 230 cases in total, 
once  more  pointed  out  that  the  most  frequent 
underlying condition for zygomycosis is hematological 
malignancy  (44%  of  all  cases),  whereas  diabetes  is 
only present in 17 % of all cases.
99 This is controversial 
to a study by,
103 reporting that diabetes account in 36 % 
of all cases to glomeromycota-infection. One possible 
explanation for this contrast might be the high increase 
of immunocompromised hosts in the recent decade.
99
The  presence  of  available  free  iron  predisposes  to 
zygomycosis.
103 The  application  of  the  iron  chelator 
deferoxamine  allows  the  fungus  to  utilize 
deferoxamine-bound  iron  by  recognizing  it  as  a 
siderophore  and  enable  it  to  acquire  the  – for  the 
fungus  inevitable  – iron  via  siderophore-specific 
mechanism/high  affinity  non-reductive  mechanism 
(sufficient  levels  of  iron  increases  the  ability 
proliferation  and  tissue  penetration  for  the  fungus). 
Other  chelators  (i.e.,  deferasirox)  do  not  allow  iron 
utilization and may decrease the risk of infection.
107,108
Antifungal prophylaxis with voriconazole also appears 
to be associated with an increased risk of developing 
zygomycosis.
85 For  successful  eradication  of  these 
pathogens a multifactorial treatment strategy is needed. 
This includes reducing the predisposing factors of the 
patient,  surgical  debridement  and  application  of 
antifungal  therapy.  Amphotericin  B,  especially  new 
lipid formulations, is still the agent of choice, and data 
exist  that  suggest  a  combinational  therapy  with 
posaconazole as promising.
85,109,110,111,112,113
Conclusion: With invasive mould infections becoming 
increasingly important, including those caused by rare, 
unusual pathogens, the epidemiology of IFIs is shifting 
in Europe. In some populations mould infections have Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
already  overtaken  candidiasis,  which  was  once  the 
predominant  type  of  IFIs.  Reasons  for  this  shift  are 
multifactorial, but the augmented use of fluconazole as 
prophylaxis  may  account,  at  least  in  part,  for  this 
phenomenon,  especially  regarding  infections  with 
previously rare pathogens that occur as breakthrough 
infections. The management of IFIs is  challenging –
complicated  by  the  difficulty  in  diagnosis  and 
increasing  resistance  of  the  pathogens  to  available 
antifungal drugs. 
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